Lexaria shareholders approve reverse stock split; company granted two Canadian patents

Lexaria Bioscience Corp.

Shareholders approved reverse stock split with ratio between 2:1 and 12:1 (67% for).
Entered 3-month investor relations contract with Andrew Barwicki Inc. for $99,500.
Granted Canadian patent for DehydraTECH in ready-to-drink beverages (expires Dec 2036).
Granted Canadian patent for tobacco leaves infused with lipophilic agents (expires Sep 2039).
Total granted patents now 37 worldwide.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lexaria Bioscience Corp. shareholders approved To approve a reverse stock split with such ratio to be not less than 2 current shares for one post reverse stock split share and no more than 12 current shares for one post reverse stock split. at the 2023-10-10 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-10-10

Exact text from the filing

Matter Being Voted On For Against/ Withheld Abstain Broker Non-Vote Percent Approved By 1 To Approve a Reverse Stock Split with such ratio to be not less than 2 current shares for one post reverse stock split share and no more than 12 current shares for one post reverse stock split. 3,120,754 1,546,507 13,453 0 67 %

View on SEC.gov

49 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-23-001812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.